



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	323004	Sel-E Plus
ARTG entry for	Medicine Listed	
Sponsor	Interclinical Laboratories Pty Ltd	
Postal Address	PO Box 6474, ALEXANDRIA, NSW, 2015 Australia	
ARTG Start Date	11/09/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Sel-E Plus

Product Type	Single Medicine Product	Effective Date	11/09/2019
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Helps reduce/decrease free radical damage to body cells
Maintain/support general health and wellbeing
Maintain/support healthy thyroid gland function
Maintain/support healthy thyroid hormones
Aid/assist thyroid hormone production
Maintain/support immune system health
Maintain/support healthy immune system function
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
Maintain/support preconception health in healthy males
Maintain/support reproductive system health in males
Maintain/support sperm health in healthy males
Maintain/support sperm motility in healthy males
Maintain/support sperm production in healthy males
Maintain/support wound healing

Indication Requirements

Product presentation must not imply or refer to infertility.
Product presentation must not imply or refer to any thyroid related diseases.
Product presentation must not imply or refer to serious immunological diseases.



Australian Government
Department of Health
 Therapeutic Goods Administration

If directed to women, Label statement: Advise your doctor of any medicine you take during pregnancy, particularly in your first trimester.

Label statement: If symptoms persist, talk to your health professional.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.

Adults only.

Not recommended for use by pregnant and lactating women (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1 . Formulation 1

Dosage Form Tablet, uncoated

Route of Administration Oral

Visual Identification

Active Ingredients

d-alpha-tocopherol	22.88 mg
glutathione	25 mg
mixed (high-alpha type) tocopherols concentrate	8.97 mg
mixed (low-alpha type) tocopherols concentrate	12.73 mg
palm tocotrienols complex	4.4 mg
selenomethionine	124.19 microgram
Equivalent: selenium	50 microgram

Other Ingredients (Excipients)

- calcium carbonate
- calcium hydrogen phosphate
- colloidal anhydrous silica
- croscarmellose sodium
- magnesium stearate
- maltodextrin
- microcrystalline cellulose
- modified food starch
- Palm Fruit Oil
- povidone
- Rape Seed Oil
- Rice bran
- Sunflower Oil

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.